ArticleScientific reports2025
Bioelectrical impedance analysis-derived phase angle predicts osteosarcopenia and mortality in patients with chronic liver disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioimpedance Analysis to Predict Clinical Outcomes of Liver Cirrhosis in a Prospective Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Longitudinal study on the relationship between extracellular water distribution changes and muscle mass in severe sarcopenia patients using multi-frequency bioelectrical impedance analysis combined with phase angle measurements.European geriatric medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcopenia, the coexistence of osteoporosis and sarcopenia, is linked to adverse clinical outcomes, emphasizing the need for routine assessment of this comorbidity. Phase angle (PhA), measured by bioelectrical impedance analysis (BIA), reflects cellular health (vitality and integrity) and nutritional status. This study investigated the relationship between PhA and osteosarcopenia or mortality and its predictive potential for both clinical events in patients with chronic liver disease (CLD). A retrospective study included 316 patients with CLD, 161 with cirrhosis. PhA was measured using direct segmental multi-frequency BIA. Osteoporosis and sarcopenia were diagnosed according to the World Health Organization and Japan Society of Hepatology criteria, respectively. Osteosarcopenia was present in 57 patients (18.0%). Over a median follow-up of 63.3 months, 47 liver-related deaths (29.2%) occurred among cirrhotic patients. Multivariate analysis identified low PhA as an independent risk factor for osteosarcopenia (odds ratio, 0.147; p < 0.001). The optimal PhA cutoff for predicting osteosarcopenia was 4.3° (sensitivity/specificity, 0.737/0.811). In patients with cirrhosis, survival rates were significantly lower in those with PhA < 4.3° compared to PhA ≥ 4.3° (p < 0.001). Multivariate analysis identified PhA < 4.3° as an independent predictor of mortality (hazard ratio, 2.588; p = 0.008). PhA, derived from BIA, was strongly associated with osteosarcopenia and mortality, making it a valuable indicator for simultaneously predicting these adverse outcomes in patients with CLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.